海峡药学
海峽藥學
해협약학
STRAIT PHARMACEUTICAL JOURNAL
2015年
7期
78-80
,共3页
慢性心衰%肌钙蛋白%血浆脑钠肽%风险评估
慢性心衰%肌鈣蛋白%血漿腦鈉肽%風險評估
만성심쇠%기개단백%혈장뇌납태%풍험평고
Chronic heart failure%Troponin%Plasma brain natriuretic peptide%Risk assessment
目的:分析慢性心力衰竭(CHF)患者血浆脑钠肽(BNP)与肌钙蛋白(cTn)T的水平变化,同时对其在预测 CHF 并发不良心血管事件(MACE)中的价值进行研究。方法根据纽约心脏病学会(NYHA)心功能分级标准随机选取心功能 I-IV级的 CHF 患者各20例,将其分成1级组,2级组,3级组,4级组;同时选取20例健康者作为对照组,分别测定各观察对象的血浆 BNP、cTnT、心肌酶水平,同时进行各组间比较。所有患者规范治疗下随访一年,比较各组MACE发生情况。结果5组中,4级组血浆BNP水平最高,对照组与1级组间比较基本无差异,其余各组间比较差异显著(P<0.01),血浆BNP水平由高至低依次为4级组、3级组、2级组、对照组与1级组;各组肌酸激酶(CK)水平及肌酸激酶同工酶(CK-MB)水平比较无差异(P>0.05);cTnT水平由高至低依次为4级组、3级组、2级组、对照组与1级组,各组比较差异具有统计学意义(P<0.01)。随访一年,2级组-4级组发生MACE分别为2例、6例和13例,且6例死亡者均发生在4级组,比较发生和未发生 MACE 患者的原始血浆BNP、cTnT水平,差异有显著性(P<0.01)。结论血浆BNP水平与cTnT水平与患者心力衰竭程度关系密切,并能较好的预测MACE发生。
目的:分析慢性心力衰竭(CHF)患者血漿腦鈉肽(BNP)與肌鈣蛋白(cTn)T的水平變化,同時對其在預測 CHF 併髮不良心血管事件(MACE)中的價值進行研究。方法根據紐約心髒病學會(NYHA)心功能分級標準隨機選取心功能 I-IV級的 CHF 患者各20例,將其分成1級組,2級組,3級組,4級組;同時選取20例健康者作為對照組,分彆測定各觀察對象的血漿 BNP、cTnT、心肌酶水平,同時進行各組間比較。所有患者規範治療下隨訪一年,比較各組MACE髮生情況。結果5組中,4級組血漿BNP水平最高,對照組與1級組間比較基本無差異,其餘各組間比較差異顯著(P<0.01),血漿BNP水平由高至低依次為4級組、3級組、2級組、對照組與1級組;各組肌痠激酶(CK)水平及肌痠激酶同工酶(CK-MB)水平比較無差異(P>0.05);cTnT水平由高至低依次為4級組、3級組、2級組、對照組與1級組,各組比較差異具有統計學意義(P<0.01)。隨訪一年,2級組-4級組髮生MACE分彆為2例、6例和13例,且6例死亡者均髮生在4級組,比較髮生和未髮生 MACE 患者的原始血漿BNP、cTnT水平,差異有顯著性(P<0.01)。結論血漿BNP水平與cTnT水平與患者心力衰竭程度關繫密切,併能較好的預測MACE髮生。
목적:분석만성심력쇠갈(CHF)환자혈장뇌납태(BNP)여기개단백(cTn)T적수평변화,동시대기재예측 CHF 병발불양심혈관사건(MACE)중적개치진행연구。방법근거뉴약심장병학회(NYHA)심공능분급표준수궤선취심공능 I-IV급적 CHF 환자각20례,장기분성1급조,2급조,3급조,4급조;동시선취20례건강자작위대조조,분별측정각관찰대상적혈장 BNP、cTnT、심기매수평,동시진행각조간비교。소유환자규범치료하수방일년,비교각조MACE발생정황。결과5조중,4급조혈장BNP수평최고,대조조여1급조간비교기본무차이,기여각조간비교차이현저(P<0.01),혈장BNP수평유고지저의차위4급조、3급조、2급조、대조조여1급조;각조기산격매(CK)수평급기산격매동공매(CK-MB)수평비교무차이(P>0.05);cTnT수평유고지저의차위4급조、3급조、2급조、대조조여1급조,각조비교차이구유통계학의의(P<0.01)。수방일년,2급조-4급조발생MACE분별위2례、6례화13례,차6례사망자균발생재4급조,비교발생화미발생 MACE 환자적원시혈장BNP、cTnT수평,차이유현저성(P<0.01)。결론혈장BNP수평여cTnT수평여환자심력쇠갈정도관계밀절,병능교호적예측MACE발생。
OBJECTIVE To analyze the level changes of brain natriuretic peptide ( BNP) and troponin T ( cT-nT) chronie heart failure ( CHF) patients ,and to study its forecast in CHF concurrent adverse cardiovascular events (MACE).METHODS According to the New York Heart Association (NYHA) functional class standard cardiac function patients with CHF were selected and randomly divided into group Ⅰ,groups Ⅱ,groupsⅢ,groupsⅣ( each group contain 20 cases);20 cases of healthy people were also selected as control group .Plasma BNP,cTnT,cardiac enzyme levels were measured and compared between the two groups at the same time .All patients were followed up for one year after the standard treatment ,the incidence of MACE was compared among the groups .RESULTS In 5 groups ,the highest plasma BNP levels was in group Ⅳ,almost no inter-group differences between group Ⅰand con-trol group.and significant differences among remaining groups ( P<0.01 ) ,plasma BNP levels with descending order was groups Ⅳ>group Ⅲ>groups Ⅱ>control group>group Ⅰ;creatine kinase ( CK) levels and creatine kinase ( CK-MB) showed no difference among six groups ( P>0.05 ); cTnT levels with descending order was group Ⅳ>group Ⅲ>group Ⅱ>the control group=group Ⅰ,the difference was statistically significant among each group ( P<0.01 ).After one year follow-up,MACE occured in group Ⅱ,group Ⅲand group Ⅳwere 2 cases,6 cases and 13 cases,and 6 deaths occurred in group Ⅳ,the original plasma BNP and cTnT levels in MACE occurred patients were higher than no MACE patients .( P<0.01 ).CONCLUSION Plasma levels of BNP and cTnT were closely related to the degree of heart failure patients ,and can better predict the occurrence of MACE .